Journal of Endocrinological Investigation

, Volume 13, Issue 5, pp 403–406 | Cite as

Circulating somatostatin after oral glucose in hypothyroidism

  • A. W. C. Kung
  • K. S. L. Lam
  • K. K. Pun
  • C. Wang
  • R. T. T. Yeung


The response of circulating somato-statin-like immunoactivity (SLI) to oral glucose and its relation to other pancreatic islet cell hormones were studied in 10 hypothyroid subjects before and after treatment. None of the patients suffered from diabetes mellitus or obesity. Compared with normal controls, the hypothyroid subjects had higher fasting and stimulated SLI levels but lower fasting pancreatic glucagon levels. Integrated glucose and insulin responses following glucose ingestion were normal, but the peak insulin réponse was delayed to 120 min suggesting impaired pancreatic β-cell response to oral glucose. On the other hand, the peak response of plasma C-peptide was higher probably because of a reduction in metabolic clearance. In both hypothyroid subjects and controls, a significant correlation was found between the maximal increment of SLI and the maximal decrement of glucagon following oral glucose. In conclusion, plasma SLI is increased in hypothyroidism. The changes in SLI may be due to either an increased hormonal secretion or a reduced metabolic clearance in hypothyroidism. This elevated SLI might contribute to the slower gastrointestinal motility observed in hypothyroidism. Our data also suggest that the reduction in glucagon secretion may be secondary to the increase in circulating SLI.


Somatostatin hypothyroidism 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Samols E., Bonner-Weir S., Weir G.C. Intra islet insulin-glucagon-somatostatin relationship. Clin. Endocrinol. Metab. 15: 33, 1986.PubMedCrossRefGoogle Scholar
  2. 2.
    Berelowitz M., Maeda K., Harris S., Frohman L.A. The effect of alterations in the pituitary-thyroid axis on hypothalamic somatostatin content and in vitro release of somatostatin-like immunoreactivity. Endocrinology 107: 24, 1980.PubMedCrossRefGoogle Scholar
  3. 3.
    Lamberg B.A. Glucose metabolism in thyroid disease. Acta. Med. Scand. 178: 351, 1965.PubMedCrossRefGoogle Scholar
  4. 4.
    Andreani D., Menzinger G., Fallucca F., Aliberti G., Tamburrano G., Cassano C. Insulin levels in thyrotoxicosis and primary myxoedema: response of intravenous glucose and glucagon. Diabetologia 6: 1, 1970.PubMedCrossRefGoogle Scholar
  5. 5.
    Skare S., Hanssen K.F., Norman N. Plasma somatostatin is elevated in primary hypothyroidism compared with hyperthyroidism. Acta Endocrinol. (Copenh.) 111: 331, 1986.Google Scholar
  6. 6.
    Ahren B., Lundquist I. Insulin secretory response to different secretogogues in hyper-and hypothyroid mice. Acta Endocrinol. (Copenh.) 97: 508, 1981.Google Scholar
  7. 7.
    Holdsworth C.D., Besser G.M. Influence of gastric emptying-rate and of insulin response on oral glucose tolerance in thyroid disease. Lancet 2: 700, 1986.Google Scholar
  8. 8.
    Beer S.F., Parr J.H.Y., Temple R.C., Hales C.N. The effect of thyroid disease on proinsulin and C-peptide levels. Clin. Endocrinol. (Oxf.) 30: 379, 1989.CrossRefGoogle Scholar
  9. 9.
    Felt V. C. peptide during glucose loading in myxoedema. Horm. Metab. Res. 20: 375, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Lam S.K., Wong H., Ng M.M.T. Hypersomatostatinaemia in duodenal ulcer. J. Gastroenterol. Hepatol. 1: 119, 1986.CrossRefGoogle Scholar
  11. 11.
    Heding L.G. Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia 7: 10, 1971.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuzuya H., Blix P.M., Horwitz D.L., Steinder D.F., Rubenstein A.H. Determination of free and total insulin and C-peptide in insulin-treated diabetes. Diabetes 26: 22, 1977.PubMedCrossRefGoogle Scholar
  13. 13.
    Seltzer H.S., Allen E.W., Herron A.L., Brennan M.T. Insulin secretion in response to glycaemic stimulus: relation of delay initial release to carbohydrate intolerance in mild diabetes mellitus. J. Clin. Invest. 46: 323, 1967.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Shah J.H. Hypoinsulinemia of hypothyroidism. Arch. Intern. Med. 132: 657, 1973.PubMedCrossRefGoogle Scholar
  15. 15.
    Polonsky K., Jaspan J., Pugh W., Cohen D., Schneider M., Schwartz T. Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction J.Clin. Invest. 72: 1114, 1983.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Klaff L.J., Taborsky G.J. Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycaemia. Diabetes 36: 592, 1987.PubMedCrossRefGoogle Scholar
  17. 17.
    Duret R.L., Bastenie P.A. Intestinal disorders in hypothyroidism. Clinical and manometric study. Am. J. Dig. Dis. 16: 723, 1971.PubMedCrossRefGoogle Scholar
  18. 18.
    Larsson L.I., Gotermann N., De Magistris L., Rehfeld J.F., Schwartz T.W. Somatostatin cell processes as pathways for paracrine secretion. Science 205: 1393, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Gerich J.E. Somatostatin. In: Brownlee M. (Ed.), Handbook of Diabetes Mellitus. Garland STPM Press, New York, London, 1981, vol. 1, p. 297.Google Scholar
  20. 20.
    Dubois A., Goldman J. Gastric secretion and emptying in hypothyroidism. Dig. Dis. Sci. 29: 407, 1984.PubMedCrossRefGoogle Scholar
  21. 21.
    Taborsky G.T. Jr. Evidence of a paracrine role for pancreatic somatostatin in vivo. Am. J.Physiol. 245: 598, 1983.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1990

Authors and Affiliations

  • A. W. C. Kung
    • 1
  • K. S. L. Lam
    • 1
  • K. K. Pun
    • 1
  • C. Wang
    • 1
  • R. T. T. Yeung
    • 1
  1. 1.Department of MedicineUniversity of Hong Kong, Queen Mary HospitalHong Kong

Personalised recommendations